Now, with the publication of ODYSSEY Outcomes, which demonstrated an associated, all-cause mortality reduction benefit, how do you view the foundational role of PCSK9 inhibitors in the CV risk treatment plan for high-risk patient populations?

Now, with the publication of ODYSSEY Outcomes, which demonstrated an associated, all-cause mortality reduction benefit, how do you view the foundational role of PCSK9 inhibitors in the CV risk treatment plan for high-risk patient populations?

CLICK HERE FOR CME CREDIT

Now, with the publication of ODYSSEY Outcomes, which demonstrated an associated, all-cause mortality reduction benefit, how do you view the foundational role of PCSK9 inhibitors in the CV risk treatment plan for high-risk patient populations?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Stephen Nicholls, MD

Stephen Nicholls, MD

SAHMRI Deputy Director and Heart Foundation Heart Health Theme Leader Professor of Cardiology University of Adelaide Consultant Cardiologist Royal Adelaide Hospital Adelaide, Australia